<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01995136</url>
  </required_header>
  <id_info>
    <org_study_id>M-13-047</org_study_id>
    <secondary_id>UMIN000011621</secondary_id>
    <nct_id>NCT01995136</nct_id>
  </id_info>
  <brief_title>Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma</brief_title>
  <official_title>Investigation of the Effect of Travoprost Ophthalmic Solution of Lowering Intraocular Pressure in Patients With Normal Tension Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate IOP reduction efficacy of travoprost 0.004%
      ophthalmic solution (TRAVATAN Z®) in subjects with normal tension glaucoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12</measure>
    <time_frame>Baseline (Day 0), Week 4, Week 8, Week 12</time_frame>
    <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data at 9:00 AM from Weeks 4, 8, and 12 were pooled. A more negative change indicates a greater amount of improvement. One eye (study eye) was subject to analysis.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Normal Tension Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>TRAVATAN Z</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Ophthalmic Solution 0.004%, 1 drop instilled in each eye once daily at 9PM for 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution 0.004%</intervention_name>
    <description>benzalkonium chloride (BAC) free</description>
    <arm_group_label>TRAVATAN Z</arm_group_label>
    <other_name>TRAVATAN Z®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of normal tension glaucoma.

          -  Must sign an Informed Consent form.

          -  IOP within protocol-specified range.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Pregnant and lactating women, or women who intend to become pregnant during the study
             period.

          -  Advanced and serious glaucoma, as specified in protocol.

          -  Complicated chronic or recurrent uveitis, scleritis or corneal herpes.

          -  History of ocular trauma, intraocular surgery or laser surgery for the included eye.

          -  Ocular-infection and severe ocular complication.

          -  Best-corrected visual acuity (BCVA) worse than 0.2 decimal.

          -  Difficulty in conducting applanation tonometry for the included eye as determined by
             the doctor.

          -  Severe or serious hypersensitivity to prostaglandin analogues or any ingredients used
             in the study.

          -  Use of IOP lowering ophthalmic solutions other than TRAVATAN Z® or oral carbonic
             anhydrase inhibitor (Diamox, etc.) during the study period.

          -  Use of any adrenocorticosteroids during the study period.

          -  Use of IOP lowering ophthalmic solution within the past 30 days.

          -  Regarded by doctor as not suitable for study participation.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danyel Carr, MS</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Japan, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alcon Japan, Ltd.</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <results_first_submitted>June 25, 2015</results_first_submitted>
  <results_first_submitted_qc>June 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 20, 2015</results_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Ocular hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Low Tension Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 5 study sites located in Japan.</recruitment_details>
      <pre_assignment_details>This reporting group includes all enrolled subjects (32).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TRAVATAN Z</title>
          <description>Ophthalmic Solution, 1 drop instilled in each eye once daily at 9PM for 3 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Change in residence</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all enrolled subjects minus any subjects with all missing data and/or critical protocol deviation/s.</population>
      <group_list>
        <group group_id="B1">
          <title>TRAVATAN Z</title>
          <description>Ophthalmic solution, 1 drop instilled in each eye once daily at 9PM for 3 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline IOP</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>9:00 AM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.55" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1:00 PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.72" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5:00 PM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.73" spread="2.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12</title>
        <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data at 9:00 AM from Weeks 4, 8, and 12 were pooled. A more negative change indicates a greater amount of improvement. One eye (study eye) was subject to analysis.</description>
        <time_frame>Baseline (Day 0), Week 4, Week 8, Week 12</time_frame>
        <population>This analysis population includes all enrolled subjects minus any subjects with all missing data and/or critical protocol deviation/s.</population>
        <group_list>
          <group group_id="O1">
            <title>TRAVATAN Z</title>
            <description>Ophthalmic Solution, 1 drop instilled in each eye once daily at 9PM for 3 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in IOP (9:00 AM) at Week 4, Week 8, and Week 12</title>
          <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data at 9:00 AM from Weeks 4, 8, and 12 were pooled. A more negative change indicates a greater amount of improvement. One eye (study eye) was subject to analysis.</description>
          <population>This analysis population includes all enrolled subjects minus any subjects with all missing data and/or critical protocol deviation/s.</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.55" lower_limit="15.88" upper_limit="17.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.37" lower_limit="-3.90" upper_limit="-2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected for the duration of the study (Sep 2013 - Jun 2014). This analysis population includes all subjects enrolled in the study, minus any subject whose safety evaluation data is all missed (1 subject).</time_frame>
      <desc>An AE was defined as any medically undesirable event that develops in a subject that received the study drug regardless of causal relationship with the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>TRAVATAN Z</title>
          <description>Ophthalmic Solution, 1 drop instilled in each eye once daily at 9PM for 3 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Manager, Phase IV</name_or_title>
      <organization>Alcon Japan, Ltd.</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

